LEADER 01541oam  2200421Ia 450 
001 9910698139103321
005 20100112152118.0
035   $a(CKB)5470000002395591
035   $a(OCoLC)316342011
035   $a(EXLCZ)995470000002395591
100   $a20090319d2009      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eclinical pharmacology section of labeling for human prescription drug and biological products : content and format
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) :$cCenter for Biologics Evaluation and Research (CBER),$d[2009]
215   $a11 pages $cdigital, PDF file
300   $aTitle from title screen (viewed on Mar. 19, 2009).
300   $a"Draft guidance."
300   $a"February 2009."
517   $aGuidance for industry 
606   $aDrugs$xLabeling$zUnited States
606   $aBiological products$xLabeling$zUnited States
615  0$aDrugs$xLabeling
615  0$aBiological products$xLabeling
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bCDS
801  2$bGPO
906   $aBOOK
912   $a9910698139103321
996   $aGuidance for industry$93434577
997   $aUNINA